Back to search results

2-HOBA for Long COVID POTS

This study is looking at how 2-HOBA might help people with Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS). LCPOTS can cause symptoms like fatigue and dizziness after a COVID-19 infection. Researchers believe that in LCPOTS, there's an ongoing immune response due to certain immune cells (monocyte/T cell doublets) and changes in blood vessel function. This study will compare 2-HOBA to a placebo (an inactive substance) over 28 days. They will measure the levels of these immune cells and how blood vessels in the abdomen respond to see if 2-HOBA can reduce the immune activation and improve blood vessel function. You may be able to join if you are an adult diagnosed with both Long COVID and POTS.

Study design
This study plans to enroll 50 participants who will be randomly assigned to receive either 2-HOBA or a placebo.
What's involved
You will have measurements taken at the beginning of the study and again after 28 days of treatment. These measurements include levels of certain immune cells and how your blood vessels respond during a head-up tilt test.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for changes in their condition over 28 days of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07189936

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

Recruiting
PHASE2Ages 18+InterventionalTreatment
Vanderbilt University Medical Center
~50 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:To Measure levels of circulating monocyte/ T cell doublets at BaselineTo measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatmentTo measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatmentTo Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBATo Measure Splanchnic venous capacitance after 28 days of Treatment with PlaceboTo Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effect IsoLG-adducts (2-HOBA) measured by levels of monocyte/T cell doublets in LCPOTS.
Measured over Baseline (Day 0) to after 28 days of treatment
+1 more outcome measured

Conditions

Post-Acute COVID-19 Syndrome
Postural Tachycardia Syndrome (POTS)
SARS CoV 2 Infection
Long COVID19

Explore related trials

Post-Acute Sequelae of COVID-19Postural Orthostatic Tachycardia Syndrome

NCT07189936

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cyndya Shibao

    Nashville, Tennesseestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Cyndya Shibao, M.D · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Who to contact

Marwa Mohamed, PhD
[email protected]
6159702384
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Effect IsoLG-adducts (2-HOBA) measured by levels of monocyte/T cell doublets in LCPOTS.Baseline (Day 0) to after 28 days of treatment

    The effect of 28-day treatment with Iso-LG-adduct scavenger, 2-hydroxybenzylamine (2-HOBA) versus placebo on circulating monocyte/ T cell doublets, and inflammatory cytokines and compare it to the placebo

  • Changes in Splanchnic venous capacitance before and after 28 days of treatmentDay 0- Day 28 days

    Changes in Splanchnic venous capacitance at 30 mins Head up tilt, before and after 28 days of treatment and compare it with 2-HOBA group with placebo group